201 related articles for article (PubMed ID: 22826745)
21. [Drugs for antiretroviral therapy. The costs of HAART].
Jablonowski H
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
[No Abstract] [Full Text] [Related]
22. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
[TBL] [Abstract][Full Text] [Related]
23. AIDS is your business.
Rosen S; Simon J; Vincent JR; MacLeod W; Fox M; Thea DM
Harv Bus Rev; 2003 Feb; 81(2):80-7, 125. PubMed ID: 12577655
[TBL] [Abstract][Full Text] [Related]
24. Costing universal access of highly active antiretroviral therapy in Benin.
Hounton SH; Akonde A; Zannou DM; Bashi J; Meda N; Newlands D
AIDS Care; 2008 May; 20(5):582-7. PubMed ID: 18484329
[TBL] [Abstract][Full Text] [Related]
25. Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon.
Muko KN; Ngwa VC; Chigang LC; Ngwa IG; Meiburg A; Shu EN
SAHARA J; 2004 Aug; 1(2):107-13. PubMed ID: 17601016
[TBL] [Abstract][Full Text] [Related]
26. What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria?
Aliyu HB; Chuku NN; Kola-Jebutu A; Abubakar Z; Torpey K; Chabikuli ON
J Acquir Immune Defic Syndr; 2012 Oct; 61(2):221-5. PubMed ID: 22820805
[TBL] [Abstract][Full Text] [Related]
27. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
[TBL] [Abstract][Full Text] [Related]
28. Effect of antiretroviral therapy on all-cause mortality among people living with HIV/AIDS in Ghana using Mahalanobis distant metric matching within propensity score caliper analysis: A retrospective cohort study.
Dwomoh D; Tambaa C; Ayisi Addo S; Wiah E; Abdulai M; Bosomprah S
PLoS One; 2018; 13(9):e0203461. PubMed ID: 30192892
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
30. What Is the Economic Burden of Subsidized HIV/AIDS Treatment Services on Patients in Nigeria and Is This Burden Catastrophic to Households?
Etiaba E; Onwujekwe O; Torpey K; Uzochukwu B; Chiegil R
PLoS One; 2016; 11(12):e0167117. PubMed ID: 27911921
[TBL] [Abstract][Full Text] [Related]
31. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.
Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD;
Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308
[TBL] [Abstract][Full Text] [Related]
32. The financial burden of HIV care, including antiretroviral therapy, on patients in three sites in Indonesia.
Riyarto S; Hidayat B; Johns B; Probandari A; Mahendradhata Y; Utarini A; Trisnantoro L; Flessenkaemper S
Health Policy Plan; 2010 Jul; 25(4):272-82. PubMed ID: 20156918
[TBL] [Abstract][Full Text] [Related]
33. Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal.
Deghaye N; Pawinski RA; Desmond C
S Afr Med J; 2006 Feb; 96(2):140-3. PubMed ID: 16532083
[TBL] [Abstract][Full Text] [Related]
34. Costing of scaling up HIV/AIDS treatment in Mexico.
Bautista-Arredondo S; Dmytraczenko T; Kombe G; Bertozzi SM
Salud Publica Mex; 2008; 50 Suppl 4():S437-44. PubMed ID: 19082254
[TBL] [Abstract][Full Text] [Related]
35. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
[TBL] [Abstract][Full Text] [Related]
36. Examining geographic and socio-economic differences in outpatient and inpatient consumer expenditures for treating HIV/AIDS in Nigeria.
Onwujekwe OE; Ibe O; Torpey K; Dada S; Uzochukwu B; Sanwo O
J Int AIDS Soc; 2016; 19(1):20588. PubMed ID: 26838093
[TBL] [Abstract][Full Text] [Related]
37. The clinical and economic efficacy of HAART: a shift from inpatient medical to outpatient pharmaceutical care for HIV/AIDS patients in Northeastern Italy.
Tramarin A; J Postma M; Gerzeli S; Campostrini S; Starace F;
AIDS Care; 2004 Feb; 16(2):213-8. PubMed ID: 14676019
[No Abstract] [Full Text] [Related]
38. The impact of integrating food supplementation, nutritional education and HAART (Highly Active Antiretroviral Therapy) on the nutritional status of patients living with HIV/AIDS in Mozambique: results from the DREAM Programme.
Scarcella P; Buonomo E; Zimba I; Doro Altan AM; Germano P; Palombi L; Marazzi MC
Ig Sanita Pubbl; 2011; 67(1):41-52. PubMed ID: 21468153
[TBL] [Abstract][Full Text] [Related]
39. Study: HAART less costly than treatment for AIDS. Annual health care cost lowered by 31%.
AIDS Alert; 2001 Feb; 16(2):26-7. PubMed ID: 15446225
[TBL] [Abstract][Full Text] [Related]
40. [Cost of HIV treatment in highly active antiretroviral therapy in Japan].
Kimura H
Nihon Rinsho; 2002 Apr; 60(4):813-6. PubMed ID: 11968794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
